Does the ATA Risk Stratification Apply to Patients with Papillary Thyroid Microcarcinoma?
The incidence of papillary thyroid microcarcinoma (PTMC) has increased over the past decade. The American Thyroid Association (ATA) suggests that these patients may undergo either thyroid lobectomy or active surveillance. It remains unclear whether there exists a subgroup of PTMC patients who may benefit from more aggressive treatment due to increased risk of recurrence.
We retrospectively reviewed 357 patients with PTMC who underwent surgery at a single institution from 2004 to 2016. Patients were classified according to 2015 ATA risk stratification for structural disease recurrence. Demographic, oncologic, and clinicopathologic data were compared between groups.
Out of 357 patients, 246 were classified as low-risk PTMC, 93 were intermediate-risk, and 18 were high-risk. There were more male patients in the high-risk group (38.9%) than the intermediate- (31.2%) or low-risk groups (15.4%) (p < 0.001). Patients with low-risk microcarcinomas were more likely to have an incidental PTMC when compared to intermediate- or high-risk groups (98[39.8%], 15[16.1%], 1[5.6%], respectively, p < 0.001). Patients with high-risk PTMCs, compared to those with intermediate- and low-risk PTMCs, were more likely to have rising postoperative thyroglobulin levels after total thyroidectomy (6[40.0%], 4[5.1%], 9[5.7%], respectively, p = 0.001) and structural recurrence after lobectomy or total thyroidectomy (3[16.7%], 0[0%], 0[0%], respectively, p < 0.001). The median follow-up time was 17.5 (IQR 3–55) months.
Patients with high-risk PTMC have an increased risk of recurrence when compared to low- and intermediate-risk microcarcinomas, whereas intermediate-risk PTMC may behave similarly to low-risk tumors. ATA risk stratification may inform clinical decision making for patients with PTMC.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Human and animal rights
The study was approved by the institutional review board at Weill Cornell Medicine.
- 9.Frangos S, Iakovou IP, Marlowe RJ et al (2015) Difficulties in deciding whether to ablate patients with putatively “low-intermediate-risk” differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study. Eur J Nucl Med Mol Imaging 42:2045–2055. https://doi.org/10.1007/s00259-015-3124-4 CrossRefPubMedGoogle Scholar
- 13.Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133. https://doi.org/10.1089/thy.2015.0020 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Tuttle RM, Tala H, Shah J et al (2010) Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341–1349. https://doi.org/10.1089/thy.2010.0178 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Arora N, Turbendian HK, Scognamiglio T, et al. (2008) Extrathyroidal extension is not all equal: Implications of macroscopic versus microscopic extent in papillary thyroid carcinoma. Surgery 144:942–7; discussion 947. doi: 10.1016/j.surg.2008.07.023Google Scholar
- 26.Kuo EJ, Goffredo P, Sosa JA, Roman SA (2013) Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis. Thyroid 23:1305–1311. https://doi.org/10.1089/thy.2012.0563 CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Brito JP, Ito Y, Miyauchi A, Tuttle RM (2016) A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and surgery in papillary microcarcinoma. Thyroid 26:144–149. https://doi.org/10.1089/thy.2015.0178 CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Durante C, Montesano T, Attard M et al (2012) Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? J Clin Endocrinol Metab 97:2748–2753. https://doi.org/10.1210/jc.2012-1123 CrossRefPubMedGoogle Scholar
- 32.Ibrahimpasic T, Nixon IJ, Palmer FL et al (2012) Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer–is there a need for radioactive iodine therapy? Surgery 152:1096–1105. https://doi.org/10.1016/j.surg.2012.08.034 CrossRefPubMedGoogle Scholar